Form 4: SANUWAVE Health Director, Jeffrey Blizard, Reports Stock Option Grant

Director Jeffrey Blizard reports the acquisition of stock options in SANUWAVE Health, Inc.

Summary

• On October 22, 2024, Jeffrey Blizard, a director of SANUWAVE Health, Inc., reported the acquisition of stock options.
• These options include the right to buy 41,333 shares of common stock at an exercise price of $14.2, expiring on October 22, 2034.
• The options will vest over three years in 12 equal quarterly installments.
• Blizard also acquired options to buy 1,559 shares of common stock at an exercise price of $22.76, expiring on December 31, 2029, which were fully vested at the grant date.
• The transactions were reported on March 18, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is generally viewed as a positive incentive for management but doesn't necessarily indicate strong positive or negative performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule for the larger option grant encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the healthcare industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like healthcare.
• The vesting schedule of three years is fairly standard, aligning with typical performance evaluation cycles.
• The exercise prices are set at or above the market price at the time of grant, which is a common practice to incentivize future performance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director to improve company performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates